Riboxinum Aveksima - instructions for use, dosage, adverse effects, contraindications

excipients for the shell: methylcellulose water soluble 4.41 mg, polysorbate 80 (tween 80) 3.0 mg, titanium dioxide (titanium dioxide) 0.4 mg, beeswax 0.15 mg, tropeolin O 0.04 mg.

Description:Round, biconvex tablets covered with a film membrane, from light yellow to yellow-orange color. On the cross-section, two layers are visible, the color of the inner layer is white.

Pharmacotherapeutic group:metabolic

ATX: & nbsp

C.01.E.B Other drugs for the treatment of heart disease

Pharmacodynamics:

Inosine belongs to the group of drugs that regulate metabolic processes. The drug is a precursor of the synthesis of purine nucleotides: adenosine triphosphate and guanosine triphosphate. Has antihypoxic, metabolic and antiarrhythmic effect. Increases the energy balance of the myocardium, improves coronary circulation, prevents consequences intraoperative kidney ischemia. It takes a direct part in the exchange of glucose and promotes the activation of metabolism in conditions of hypoxia and in the absence of adenosine triphosphate.

Activates the metabolism of pyruvic acid to ensure a normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of Krebs cycles. Penetrating into cells, increases the energy level, has a positive effect on the metabolic processes in the myocardium, increases the strength of the heart contractions and promotes more complete relaxation of the myocardium in diastole, resulting in an increase in the shock volume of blood.

Reduces platelet aggregation, activates the regeneration of tissues (especially the myocardium and mucous membrane of the gastrointestinal tract).

Pharmacokinetics:

It is well absorbed in the gastrointestinal tract. Metabolised in the liver with the formation of glucuronic acid and its subsequent oxidation. In a small amount is excreted by the kidneys.

Indications:

Assign adults in the complex therapy of coronary heart disease, after a heart attack, myocardial infarction, heart rhythm disorders due to the use of cardiac glycosides.

Contraindications:

Hypersensitivity to the drug, gout, hyperuricemia.

Fructose intolerance and glucose / galactose absorption disorder or sugar / isomaltase deficiency.

Carefully:

Renal insufficiency, diabetes mellitus.

Pregnancy and lactation:

The safety of the drug Riboxin during pregnancy and lactation is not established. Riboxin is contraindicated during pregnancy. For the duration of treatment with Riboxin, breastfeeding should be stopped.

Dosing and Administration:

Riboxin is prescribed inside before meals.

The daily dose of the drug for oral administration is 0.6-2.4 g. In the first days of treatment, the daily dose is 0.6-0.8 g (200 mg 3-4 times a day). In case of good tolerance, the dose is increased 2-3 days to 1.2 g (0.4 g 3 times a day), if necessary - up to 2.4 g / day. Duration of treatment - from 4 weeks to 1.5-3 months. With urocoppororphy, the daily dose is 0.8 g (200 mg 4 times a day). The course of treatment - 1-3 months.

Side effects:

Allergic reactions are possible in the form of hives, itchy skin, skin hyperemia (drug withdrawal is required).

Rarely in the treatment of the drug raises the concentration of uric acid in the bloodand exacerbation of gout (with prolonged use).

Overdose:

Cases of overdose are unknown.

Interaction:

Immunosuppressants (azathioprine, antilympholine, ciclosporin, thymodepressin, etc.) with simultaneous use reduce the effectiveness of Riboxin.

Special instructions:

During the treatment with Riboxin, the concentration of uric acid in the blood and urine should be monitored.

Information for patients with diabetes: 1 tablet of the drug corresponds to 0.00641 units of bread.

Effect on the ability to drive transp. cf. and fur:

There is no evidence of a negative effect of the use of Riboxin in relation to the ability to drive a car or to control machines and mechanisms.

Form release / dosage:

Tablets, film-coated, 200 mg.

Packaging:

10 tablets in a contour cell package.

50 tablets in a can of glass or in a polymer type BP bank.

1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 contour mesh packages or a bank together with instructions for use in a pack of cardboard.

Storage conditions:

In a dry, protected from light place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LSR-009037/10

Date of registration:31.08.2010

The owner of the registration certificate:Anzhero-Sudzhensky Chemical-Pharmaceutical Plant, LLC Anzhero-Sudzhensky Chemical-Pharmaceutical Plant, LLC

Manufacturer: & nbsp

Anzhero-Sudzhensky Chemical-Pharmaceutical Plant, LLC Russia

Information update date: & nbsp22.10.2015

Illustrated instructions

Instructions

Riboxin of Avexime (Riboxin Avexima)